

# Vaia Florou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/267214/publications.pdf>

Version: 2024-02-01

26  
papers

708  
citations

1307594

7  
h-index

794594

19  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1055  
citing authors

#	ARTICLE	IF	CITATIONS
1	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	10.7	262
2	Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. , 2019, 7, 213.		118
3	Current and Future Directions for Angiosarcoma Therapy. <i>Current Treatment Options in Oncology</i> , 2018, 19, 14.	3.0	75
4	Considerations for treatment duration in responders to immune checkpoint inhibitors. , 2021, 9, e001901.		69
5	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	4.2	66
6	Current Management of Angiosarcoma: Recent Advances and Lessons From the Past. <i>Current Treatment Options in Oncology</i> , 2021, 22, 61.	3.0	21
7	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 478-482.	4.9	21
8	Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1107-1112.	4.0	15
9	Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. <i>Annals of Translational Medicine</i> , 2021, 9, 1035-1035.	1.7	9
10	The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1935-1939.	3.3	8
11	A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11547-11547.	1.6	8
12	Latest advances in adult gastrointestinal stromal tumors. <i>Future Oncology</i> , 2017, 13, 2183-2193.	2.4	7
13	Precision medicine in gastrointestinal stromal tumors. <i>Discovery Medicine</i> , 2019, 28, 267-276.	0.5	6
14	Intravenous Leiomyomatosis: A Rare Diagnosis With Aggressive Potential. <i>JCO Oncology Practice</i> , 2021, 17, 206-208.	2.9	3
15	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	1.7	3
16	Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repairâ€œDeficient Pancreatic Cancer After Planned Treatment Interruption. <i>JCO Precision Oncology</i> , 2020, 4, 780-784.	3.0	2
17	Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 387-387.	1.6	1
18	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1

#	ARTICLE	IF	CITATIONS
19	Frameshift mutations (Fsinde) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.. Journal of Clinical Oncology, 2019, 37, 2617-2617.	1.6	1
20	Cancer Immunotherapy in the Immunosuppressed Patients and Its Relevance to Clinical Practice. Journal of Immunotherapy and Precision Oncology, 2019, 2, 127-128.	1.4	1
21	Emerging mechanisms of immunotherapy resistance in sarcomas. Cancer Drug Resistance (Alhambra,) Tj ETQq1 1 0,784314 rgBT /Ov	2.1	1
22	A 51-year-old man with chronic cough and left hilar prominence. Breathe, 2021, 17, 210018.	1.3	0
23	High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2018, 36, e24109-e24109.	1.6	0
24	Safety and efficacy of olaratumab added to doxorubicin-based combination chemotherapy in the treatment of advanced soft-tissue sarcoma (STS).. Journal of Clinical Oncology, 2018, 36, e23542-e23542.	1.6	0
25	Angiosarcoma treated with checkpoint inhibitors: A single-institution experience.. Journal of Clinical Oncology, 2019, 37, e22543-e22543.	1.6	0
26	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. Journal of Immunotherapy and Precision Oncology, 2020, 3, 137-139.	1.4	0